timberwolf7 Wednesday, 12/09/20 11:46:30 AM Re: None Post # of 2570 New PR from ATNM... this comment in the write up caught my attention. Is this field really growing as they imply, ie, not a niche market, and saying they are the 'leader' rather than just one of the 'players' in this sector?? hadn't ever thought of them being a buyout candidate before this was said... ok, back to my regularly scheduled program of seeing them complete their PH 3... https://ir.actiniumpharma.com/press-releases/detail/384 "Targeted radiotherapy is witnessing a renaissance driven by strong clinical data emerging in multiple indications. This has resulted in acquisitions, new company formation and investments in new targets to pursue with radiotherapy," said Sandesh Seth, Actinium's Chairman and CEO. He continued, "Actinium is proud to have not only established ourselves as a leader in the targeted radiotherapy field and is the only company pursuing well validated targets in hematology with late stage clinical programs.